FDA approves CAR T therapy for large B-cell lymphoma developed at Penn

(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.